Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637184 | 1.00 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| SCHEMBL805212 | 1.00 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL9762430 | 0.98 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL9761871 | 0.98 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL1130360 | 0.98 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| SCHEMBL18625014 | 0.94 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| SCHEMBL9867000 | 0.91 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KMT2AHSD17B10KDM4E | |
| SCHEMBL16002857 | 0.88 | LMNA (0.54) | ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA | |
| SCHEMBL16751013 | 0.88 | LMNA (0.54) | ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA | |
| SCHEMBL16750977 | 0.88 | LMNA (0.54) | ALDH1A1SMN1; SMN2KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2019-07-03 | — | — | EP | claimed |
| WO-2018042316-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2018-03-08 | — | — | WO | claimed |
| CN-106986789-A | Hydroquinone compound and preparation method thereof and the application in antitumor or immunological regulation | 中国人民解放军军事医学科学院生物医学分析中心 | 2017-07-28 | — | — | CN | claimed |
| EP-2617779-B1 | Low odor environmentally-friendly nano-pigment inkjet ink composition | JETBEST CORP (TW) | 2014-11-05 | — | — | EP | claimed |
| CN-102770182-B | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2014-10-29 | — | — | CN | claimed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | claimed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007053773-A1 | COMPOSITIONS AND METHODS USING NICOTINIC ACID FOR TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE | HENDRIX CURT (US) | 2007-05-10 | — | — | WO | claimed |
| US-20070105793-A1 | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease | CONCOURSE HEALTH SCIENCES LLC | 2007-05-10 | — | — | US | claimed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| WO-2004113353-A1 | SILICON-COMPRISING AMINOTHIAZOLE DERIVATIVES AS CDK INHIBITORS | AMEDIS PHARMACEUTICALS LTD. (GB) | 2004-12-29 | — | — | WO | claimed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-05-26 | — | — | US | disclosed |
| US-4094957-A | CARBON DIOXIDE | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636368-B2 | Ionizable lipids for nucleic acid delivery | NSUN2, NSUN3, RNMT | ALDH1A1 1643/4885SMN1; SMN2 546/4885KMT2A 1599/4885 |
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | ALDH1A1 2348/4885SMN1; SMN2 935/4885KMT2A 722/4885 |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | ALDH1A1 1792/4885SMN1; SMN2 4589/4885KMT2A 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.